Company intelligence / Profile preview
Shanghai Huilun Pharmaceutical Co., Ltd.
Shanghai, Shanghai, Chinahuilunbio.com ↗
- Ownership
- Private
- Employees
- ~4999
- Development stage
- Commercial
01
Overview
The company has obtained over 40 clinical trial permissions approved by CFDA. 22 drugs were applied for manufacturing licenses with 10 approved. 3 Class I innovative drugs are undergoing clinical trials domestically and 1 was approved by FDA for clinical trials in the United States.
- Therapeutic areas
- Men's HealthPulmonologyOncologyInfectious DiseasesGastroenterologyCardiovascularNeurologyWomen's Health
- Modalities
- Small moleculesPROTACs
- Industry
- Biotech
02
Drug pipeline
1 assetBeyond the preview
Go deeper on Shanghai Huilun Pharmaceutical Co., Ltd..
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Clinical trials
Follow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Licensing & deals
Explore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Trace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Compare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Explore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Connect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Shanghai Huilun Pharmaceutical Co., Ltd..